Related Parties (Tables)

12 Months Ended

Dec. 31, 2018

The balances and transactions between the Company and its subsidiaries with other related parties are disclosed below:


	Loans
	Assets		Liabilities
Química da Bahia Indústria e Comércio S.A.		—		2,925
Others		490		1,146

Total as of December 31, 2018		490		4,071


	Loans
	Assets		Liabilities
Química da Bahia Indústria e Comércio S.A.		—		2,946
Others		490		1,239

Total as of December 31, 2017		490		4,185

Loans agreements have indeterminate terms and do not contain interest clauses. These are carried out due temporary excess or necessity cash of the Company, its subsidiaries, and its associates.


	Commercial transactions
	Receivables⁽¹⁾		Payables⁽¹⁾		Sales and services		Purchases		Expenses
Oxicap Indústria de Gases Ltda.		—		567		6		9,032		—
Refinaria de Petróleo Riograndense S.A.		—		24,630		—		1,008,860		—
ConectCar Soluções de Mobilidade Eletrônica S.A.		1,042		136		3,844		186		—
LA’7 Participações e Empreend. Imob. Ltda. (a)		—		117		—		—		1,469

Total as of December 31, 2018		1,042		25,450		3,850		1,018,078		1,469


	Commercial transactions
	Receivables⁽¹⁾		Payables⁽¹⁾		Sales and services		Purchases		Expenses
Oxicap Indústria de Gases Ltda.		—		1,489		6		18,108		—
Refinaria de Petróleo Riograndense S.A.		—		22,199		—		1,004,030		—
ConectCar Soluções de Mobilidade Eletrônica S.A.		1,067		31		7,239		859		—
LA’7 Participações e Empreend. Imob. Ltda. (a)		—		125		—		—		2,300

Total as of December 31, 2017		1,067		23,844		7,245		1,022,997		2,300


	Commercial transactions
	Sales and services		Purchases		Expenses
Oxicap Indústria de Gases Ltda.		6		18,079		—
Refinaria de Petróleo Riograndense S.A.		—		958,007		—
ConectCar Soluções de Mobilidade Eletrônica S.A.		13,329		1,424		—
LA’7 Participações e Empreend. Imob. Ltda. (a)		—		—		2.478

Total as of December 31, 2016		13,335		977,510		2.478

(1)	Included in “domestic trade receivables” and “domestic trade payables,” respectively.

(a)	Refers to rental contracts of 15 drugstores owned by LA’7 (16 drugstores in 2017), a company of the former shareholders of Extrafarma that are current shareholders of Ultrapar.

Expenses for Compensation of its Key Executives

The Company and its subsidiaries recognized expenses for compensation of its key executives (Company’s directors and executive officers) as shown below:


	12/31/2018		12/31/2017			12/31/2016
Short-term compensation		36,504		45,477			40,306
Stock compensation (*)		1,407		1,399			5,427
Post-employment benefits		2,278		1,096			3,336
Long-term compensation (**)		—		(6,459	)		2,473
Termination benefit		905		8,794			—

Total		41,094		50,307			51,542

(*)	Includes the reversal of expenses for the forfeiture of granted shares due to termination of executive employment (see Note 8.c).

(**)	The chief executive officer in office until October 2, 2017 was entitled to additional long-term variable compensation. This contract was terminated with the succession of the chief executive officer.

Shares Granted

The table below summarizes shares granted to the Company and its subsidiaries’ management:


Grant date	Balance of number of shares granted		Vesting period		Market price of shares on the grant date (in R$ per share)		Total grant costs, including taxes		Accumulated recognized grant costs			Accumulated unrecognized grant costs
March 13, 2017		100,000		2022 to 2024		67.99		9,378		(2,920	)		6,458
March 4, 2016		190,000		2021 to 2023		65.43		17,147		(8,252	)		8,895
December 9, 2014		400,000		2019 to 2021		50.64		27,939		(19,376	)		8,563
March 5, 2014		83,400		2019 to 2021		52.15		5,999		(4,925	)		1,074
November 7, 2012		76,664		2017 to 2019		42.90		16,139		(15,599	)		540
December 14, 2011		—		2016 to 2018		31.85		4,832		(4,832	)		—

		850,064						81,434		(55,904	)		25,530

Changes of Number of Shares Granted

The table below summarizes the changes of number of shares granted:


Balance on December 31, 2016	1,500,072
Shares granted on March 4, 2017	100,000
Forfeiture of granted shares due to termination of executive employment	(143,333	)
Shares vested and transferred	(273,341	)

Balance on December 31, 2017	1,183,398
Forfeiture of granted shares due to termination of executive employment	(216,666	)
Shares vested and transferred	(116,668	)

Balance on December 31, 2018	850,064

Restricted Stock Program

The table below summarizes the restricted and performance stock programs:


Program	Grant date		Balance of number of shares granted		Vesting period		Market price of shares on the grant date (in R$ per share)		Total grant costs, including taxes		Accumulated recognized grant costs			Accumulated unrecognized grant costs
Restricted		October 1, 2017		120,000		2023		76.38		12,642		(2,634	)		10,008
Restricted and performance		November 8, 2017		37,938		2020 to 2022		76.38		4,988		(1,523	)		3,465
Restricted and performance		April 9, 2018		92,038		2021 to 2023		68.70		12,028		(2,363	)		9,665
Restricted		September 19, 2018		80,000		2024		39.16		4,321		(180	)		4,141
Restricted		September 24, 2018		40,000		2024		36.80		2,030		(85	)		1,945

				369,976						36,009		(6,785	)		29,224

Summarized Changes of Number of Restricted and Performance Shares Granted

The table below summarizes the changes of the number of restricted and performance shares granted:


Balance on December 31, 2017	166,270

Shares granted on April 9, 2018	103,592
Shares granted on September 19, 2018	80,000
Shares granted on September 24, 2018	40,000
Forfeiture of granted shares due to termination of executive employment	(19,886	)

Balance on December 31, 2018	369,976